What Does DOJ’s New Corporate Enforcement Policy Mean for the FDA- and DEA-Regulated Industry?

Key Takeaways

• CEP offers case declination for voluntary self‑disclosures meeting four criteria
• NPAs can cut Sentencing Guidelines fines by up to 75%
• Prosecutors retain discretion; “full cooperation” remains subjective
• FDA/DEA firms must weigh early DOJ reporting against whistleblower risk
• No set timeline for declination decisions creates uncertainty for corporations

Pulse Analysis

The Justice Department’s new Corporate Enforcement and Voluntary Self‑Disclosure Policy marks a shift toward greater predictability in white‑collar prosecutions. By codifying a four‑factor test—voluntary disclosure, full cooperation, timely remediation, and absence of aggravating circumstances—the CEP gives corporations a clearer roadmap to avoid criminal charges. At the same time, the policy preserves prosecutorial leeway, especially around the nebulous definition of "full cooperation," meaning outcomes can still vary widely from case to case.

For companies operating under FDA or DEA oversight, the CEP carries particular weight. These firms already manage rigorous reporting obligations for adverse events, recalls, and suspicious orders. Voluntary self‑disclosure to DOJ can pre‑empt whistleblower actions or False Claims Act suits, potentially limiting exposure to larger civil penalties. However, the decision to self‑report must balance the benefit of a possible declination or reduced‑fine NPA against the risk of revealing sensitive information that could trigger broader investigations.

Strategically, the lack of a mandated timeline for declination decisions adds a layer of uncertainty. Corporations must therefore invest in robust internal compliance programs and maintain open channels with legal counsel to assess the timing and scope of any disclosure. As the DOJ applies the CEP to more cases, firms that proactively align their remediation and cooperation practices with the policy’s criteria will be better positioned to negotiate favorable outcomes, while those that delay may face steeper financial and reputational costs.